The compromise reached at the World Trade Organization (WTO) in June 2022 regarding COVID-19 vaccine manufacturing was a limited 'Decision on the TRIPS Agreement and Public Health,' not a full Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver as initially proposed by India and South Africa. A full TRIPS waiver would have temporarily suspended intellectual property (IP) rights (patents, copyrights, industrial designs, and undisclosed information) on all COVID-19 related health products, including vaccines, therapeutics, and diagnostics, for the duration of the pandemic. This would have allowed any country to produce or procure generic versions without fear of IP infringement.

However, the agreed-upon decision fell short of this comprehensive waiver for several reasons:

1. Limited Scope: The decision primarily focused on vaccines, excluding therapeutics and diagnostics, which were part of the original waiver proposal. This significantly narrowed its potential impact on overall pandemic response.
2. Conditional Compulsory Licensing: Instead of a blanket suspension of IP rights, the decision primarily clarified and streamlined the process for issuing compulsory licenses for vaccine production. While it eased some procedural requirements, it still required countries to follow specific steps, including notifying the WTO and meeting certain conditions, rather than automatically waiving patent protections.
3. Geographical Restrictions: The decision was primarily applicable to developing countries, with developed countries explicitly excluded from using the flexibilities for vaccine exports. This created a two-tiered system.
4. No Technology Transfer: Crucially, the decision did not mandate or facilitate the transfer of technology or know-how, which is essential for developing countries to effectively manufacture complex vaccines. Without this, simply waiving patents has limited utility.
5. Limited Duration: The decision was temporary, set to expire after five years, with a review after four years.

In essence, the compromise was a clarification of existing TRIPS flexibilities rather than a fundamental suspension of IP rights. It maintained the core framework of IP protection while offering some procedural easements, which was a far cry from the broad, automatic waiver that proponents argued was necessary to rapidly scale up global vaccine production and ensure equitable access.